0107 ECP Endeavor
BioCentury & Getty Images

Emerging Company Profile

Impact founder Hood launches Endeavor with $62M to address pulmonary diseases

Emerging Company Profile: Endeavor is starting with a hedgehog inhibitor from Eli Lilly in IPF 

With $62 million in series A financing, Endeavor is planning two Phase II clinical trials of a Lilly small molecule to treat IPF. 

Read the full 580 word article

How to gain access

Continue reading with a
two-week free trial.